HCM
TGTX icon

Hollencrest Capital Management’s TG Therapeutics TGTX Stock Holding History

Hollencrest Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$56K – 343
2018
Q3 		$56K Sell
10,000
-2,000
-17% -$22.9K ﹤0.01% 351
2018
Q2 		$158K Hold
12,000
– – 0.02% 280
2018
Q1 		$170K Hold
12,000
– – 0.02% 282
2017
Q4 		$98K Hold
12,000
– – 0.01% 309
2017
Q3 		$142K Hold
12,000
– – 0.02% 304
2017
Q2 		$121K Buy
+12,000
New +$134K 0.02% 291

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hollencrest Capital Management's TGTX Position: Q4 2018 in Review

Hollencrest Capital Management sold out of TG Therapeutics (TGTX) in Q4 2018, closing a stake of 10,000 shares — an estimated $56K sold.

Hollencrest Capital Management first reported a position in TGTX in Q2 2017 and held it in 6 quarters. The position peaked at $170K in Q1 2018. 115 funds tracked by Wall St. Rank hold TGTX as of Q4 2018.

  • Hollencrest Capital Management reported no remaining TG Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Hollencrest Capital Management sold 10,000 TG Therapeutics shares in Q4 2018, an estimated $56K.
  • Hollencrest Capital Management first reported a position in TG Therapeutics in Q2 2017 and held it in 6 quarters.
  • Hollencrest Capital Management's TG Therapeutics position peaked at $170K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2018.

Based on Hollencrest Capital Management's 13F filing for Q4 2018, filed 3 Jan 2019.